Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PBYI 
Puma Biotechnology Inc (PBYI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/11/2025: PBYI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3
1 Year Target Price $3
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -10.84% | Avg. Invested days 33 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 225.16M USD | Price to earnings Ratio 4.52 | 1Y Target Price 3 |
Price to earnings Ratio 4.52 | 1Y Target Price 3 | ||
Volume (30-day avg) 2 | Beta 1.37 | 52 Weeks Range 2.32 - 6.07 | Updated Date 09/12/2025 |
52 Weeks Range 2.32 - 6.07 | Updated Date 09/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.99 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 20.35% | Operating Margin (TTM) 12.66% |
Management Effectiveness
Return on Assets (TTM) 14.4% | Return on Equity (TTM) 63.24% |
Valuation
Trailing PE 4.52 | Forward PE 3.46 | Enterprise Value 179874253 | Price to Sales(TTM) 0.95 |
Enterprise Value 179874253 | Price to Sales(TTM) 0.95 | ||
Enterprise Value to Revenue 0.76 | Enterprise Value to EBITDA 2.84 | Shares Outstanding 50370700 | Shares Floating 38562818 |
Shares Outstanding 50370700 | Shares Floating 38562818 | ||
Percent Insiders 15.43 | Percent Institutions 68.25 |
Upturn AI SWOT
Puma Biotechnology Inc
Company Overview
History and Background
Puma Biotechnology, Inc. is a biopharmaceutical company founded in 2011. It focuses on acquiring and developing innovative products to enhance cancer care. The company's primary focus has been the development and commercialization of NERLYNXu00ae (neratinib) for HER2-positive breast cancer.
Core Business Areas
- Oncology: Puma Biotechnology focuses exclusively on the development and commercialization of therapies for various types of cancer, particularly HER2-positive breast cancer.
Leadership and Structure
Alan H. Auerbach is the Chairman, President, and CEO. The company has a standard organizational structure with departments for research, development, commercialization, and finance.
Top Products and Market Share
Key Offerings
- NERLYNX (neratinib): NERLYNX is Puma Biotechnology's primary product, an oral tyrosine kinase inhibitor approved for extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy. Market share data is variable and depends on specific treatment settings, but NERLYNX competes with other HER2-targeted therapies. Competitors include Roche (Herceptin and Perjeta), Novartis (Kisqali) and AstraZeneca (Enhertu).
Market Dynamics
Industry Overview
The oncology therapeutics market is highly competitive and rapidly evolving, with increasing demand for targeted therapies and personalized medicine. Significant innovation is driven by advancements in genomics and immunotherapy.
Positioning
Puma Biotechnology is a smaller player focused on a specific niche within the breast cancer market. Its competitive advantage lies in NERLYNX's unique indication and oral availability, though it faces challenges from more established and diversified companies.
Total Addressable Market (TAM)
The breast cancer therapeutics market is estimated to be billions of dollars annually. Puma Biotechnology is positioned to capture a portion of this TAM through NERLYNX, specifically targeting HER2-positive patients following trastuzumab treatment. Exact TAM for NERLYNX's niche is not readily available and can vary widely.
Upturn SWOT Analysis
Strengths
- Approved product (NERLYNX)
- Targeted treatment for HER2-positive breast cancer
- Oral administration convenience
Weaknesses
- Sole product dependency
- Competition from established players
- Side effect profile of NERLYNX (diarrhea)
- Small market capitalization
Opportunities
- Expansion of NERLYNX indications
- Partnerships for global commercialization
- Acquisition of new oncology assets
- Advances in cancer diagnostics to better identify NERLYNX patients.
Threats
- Generic competition
- Development of more effective therapies by competitors
- Regulatory changes
- Pricing pressures
Competitors and Market Share
Key Competitors
- ROCHE (ROG.SW)
- NOVARTIS (NOVN.SW)
- ASTRAZENECA (AZN)
Competitive Landscape
Puma Biotechnology faces significant competition from larger, more established pharmaceutical companies. Its success depends on effectively marketing NERLYNX and expanding its clinical utility.
Growth Trajectory and Initiatives
Historical Growth: Puma Biotechnology's growth has been tied to NERLYNX sales. Growth trends reflect the product's market adoption and competitive landscape.
Future Projections: Future growth depends on NERLYNX sales, potential label expansions, and new product acquisitions. Analyst estimates can be found on financial news sites.
Recent Initiatives: Recent initiatives may include efforts to expand NERLYNX's market reach, clinical trials for new indications, and strategic partnerships.
Summary
Puma Biotechnology is a small biopharmaceutical company heavily reliant on the success of NERLYNX. While NERLYNX addresses a specific need in HER2-positive breast cancer, the company faces strong competition and product safety concerns. Expansion of NERLYNX indications and strategic partnerships are crucial for long-term growth. Investors should monitor competitive developments and regulatory changes that could impact the company's future.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Puma Biotechnology Inc. Investor Relations
- SEC Filings
- Industry Reports
- Financial News Outlets
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial advice. Investment decisions should be made based on individual research and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Puma Biotechnology Inc
Exchange NASDAQ | Headquaters Los Angeles, CA, United States | ||
IPO Launch date 2012-04-24 | Founder, Chairman, President, CEO & Secretary Mr. Alan H. Auerbach | ||
Sector Healthcare | Industry Biotechnology | Full time employees 172 | |
Full time employees 172 | |||
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.